1. Jacalin-Curcumin Complex Sensitizes the Breast Cancer MDA-MB-231 Cell Line.
- Author
-
Petrova L, Gergov N, Stoup M, Zapryanova S, Van Damme EJM, Lebègue N, Liberelle M, Zasheva D, and Bogoeva V
- Subjects
- Humans, Female, MDA-MB-231 Cells, Cell Proliferation, Antigens, Neoplasm pharmacology, Cell Line, Tumor, Apoptosis, Curcumin chemistry, Breast Neoplasms metabolism, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms pathology, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use
- Abstract
Protein-drug interactions are crucial for understanding drug delivery and cell functions. Jacalin is a suitable molecule for such targeting, as it specifically recognizes the tumor-associated Thomsen-Friedenreich (TF) antigen that is expressed on the glycosylated proteins in cancer cells. The present paper describes the interaction of curcumin and jacalin, a possible carrier molecule for the delivery of antitumor drugs due to its ability to recognize tumor cells. Our results have shown that both steady-state fluorescence and fluorescent labelling of jacalin are two reliable methods to determine jacalin-curcumin interactions. The affinity of jacalin for curcumin is consistently within the micromolar range (using fluorescence and microscale thermophoresis) showing high-affinity binding of the complex. In vitro experiments on triple-negative breast cancer MDA-MB-231 cells indicated inhibition of cell growth after treating with the jacalin-curcumin complex for 48 h. The cell survival fraction was significantly reduced to 50% after combined treatment. In this paper, we report for the first time about the jacalin-curcumin interaction. We quantified this unique biomolecular interaction and gathered additional information on the binding event. We observed that the jacalin-curcumin complex inhibits the proliferation of the triple-negative breast cancer MDA-MB-231 cells.
- Published
- 2023
- Full Text
- View/download PDF